Advertisement
U.S. markets open in 9 hours 17 minutes

Delcath Systems, Inc. (DCTH)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.1800+0.2100 (+5.29%)
At close: 04:00PM EDT
4.2300 +0.05 (+1.20%)
After hours: 04:55PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close3.9700
Open3.9800
Bid3.8600 x 800
Ask3.9800 x 900
Day's Range3.9376 - 4.3300
52 Week Range2.2500 - 7.9900
Volume144,344
Avg. Volume236,490
Market Cap92.153M
Beta (5Y Monthly)0.51
PE Ratio (TTM)N/A
EPS (TTM)-3.4400
Earnings DateMar 25, 2024 - Mar 29, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for DCTH

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Delcath Systems, Inc.
    Technical Assessment: Neutral in the Intermediate-TermIn the past week, we have had little economic and EPS data, but we have had some interesting price action across the stock, bond, commodity, and currency markets. That caught us, as well as others, by surprise. But it is a big world out there and we try to avoid missing the forest for the trees!
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • PR Newswire

    Delcath Systems Appoints Martha S. Rook as Chief Operating Officer

    Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Martha S. Rook as its new Chief Operating Officer (COO).

  • PR Newswire

    Delcath Systems Announces $7 Million Private Placement

    Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that it has entered into a securities purchase agreement with certain accredited investors comprised of existing investors, Delcath Executives and members of its Board of Directors, for a private placement transaction (the "Private Placement").

  • PR Newswire

    Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as a material inducement to the employment of three individuals whose employment commenced in February 2024.